X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Glenmark Pharma with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs ACTAVIS (US) - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GLENMARK PHARMA   ACTAVIS
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
ACTAVIS
Dec-18
GLENMARK PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs93013,508-   
Low Rs5179,061-   
Sales per share (Unadj.) Rs322.63,313.6-  
Earnings per share (Unadj.) Rs28.5-1,067.3-  
Cash flow per share (Unadj.) Rs39.2349.2-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs183.013,666.9-  
Shares outstanding (eoy) m282.17332.60-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.23.4 65.9%   
Avg P/E ratio x25.4-10.6 -240.3%  
P/CF ratio (eoy) x18.532.3 57.1%  
Price / Book Value ratio x4.00.8 479.0%  
Dividend payout %7.00-   
Avg Mkt Cap Rs m204,2063,753,320 5.4%   
No. of employees `00013.716.9 81.2%   
Total wages/salary Rs m18,7180-   
Avg. sales/employee Rs Th6,636.865,212.5 10.2%   
Avg. wages/employee Rs Th1,364.70-   
Avg. net profit/employee Rs Th586.1-21,005.0 -2.8%   
INCOME DATA
Net Sales Rs m91,0311,102,090 8.3%  
Other income Rs m91421,076 4.3%   
Total revenues Rs m91,9451,123,166 8.2%   
Gross profit Rs m16,15428,880 55.9%  
Depreciation Rs m3,019471,120 0.6%   
Interest Rs m2,85663,597 4.5%   
Profit before tax Rs m11,193-484,761 -2.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0123,634 0.0%   
Tax Rs m3,155-6,143 -51.4%   
Profit after tax Rs m8,039-354,984 -2.3%  
Gross profit margin %17.72.6 677.2%  
Effective tax rate %28.21.3 2,223.9%   
Net profit margin %8.8-32.2 -27.4%  
BALANCE SHEET DATA
Current assets Rs m69,887452,020 15.5%   
Current liabilities Rs m32,879399,872 8.2%   
Net working cap to sales %40.74.7 859.2%  
Current ratio x2.11.1 188.0%  
Inventory Days Days8120 415.8%  
Debtors Days Days9366 141.0%  
Net fixed assets Rs m28,892124,750 23.2%   
Share capital Rs m2820-   
"Free" reserves Rs m51,3530-   
Net worth Rs m51,6354,545,608 1.1%   
Long term debt Rs m41,4181,600,673 2.6%   
Total assets Rs m125,9547,105,820 1.8%  
Interest coverage x4.9-6.6 -74.3%   
Debt to equity ratio x0.80.4 227.8%  
Sales to assets ratio x0.70.2 466.0%   
Return on assets %8.6-4.1 -210.9%  
Return on equity %15.6-7.8 -199.4%  
Return on capital %15.1-4.8 -311.9%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m26,5980-   
CASH FLOW
From Operations Rs m16,481393,735 4.2%  
From Investments Rs m-10,133216,306 -4.7%  
From Financial Activity Rs m-4,685-675,768 0.7%  
Net Cashflow Rs m1,770-65,398 -2.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 69.81 Rs / USD

Compare GLENMARK PHARMA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare GLENMARK PHARMA With: SUVEN LIFESCIENCES  ORCHID PHARMA LTD  J.B.CHEMICALS  DR. REDDYS LAB  VENUS REMEDIES  



Today's Market

Indian Indices End on a Positive Note; Oil & Gas and IT Stocks Witness Buying(Closing)

Indian share markets traded on a positive note most of the day and ended marginally higher. Gains were seen in the oil & gas sector and IT sector.

Related Views On News

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Just One Stock Made Buffett Billions - And Can Make You Crores(Profit Hunter)

Jun 6, 2019

Coca Cola is arguably one of Warren Buffet's best stock picks. But did you know that small investors picked up the stock five decades before Buffet? Read on...

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)

Jun 10, 2019

The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jun 18, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - IPCA LABS COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS